Abstract
Biological response modifiers (BRMs) are natural proteins that alter immune responses and that have been developed as both immunosuppressive and immunostimulating drugs. These may include natural products such as β-glucans or biotherapeutics such as monoclonal antibodies. Immunotoxicity testing of these immune modulators is not currently regulated by International Conference on Harmonization (ICH) guidelines and many of the standard immunotoxicity tests are used for understanding the pharmacology of the molecule. Since many biotherapeutics are only cross-reactive in nonhuman primates (NHPs), the standard immunotoxicity tests may need to be adapted (since rodents are the standard species used for immunotoxicity testing of small-molecule therapeutics). Unanticipated effects on the immune system may or may not be related to the mechanism of action, but would then be considered as immunotoxicity. Immunogenicity must also be assessed, which is the immune response to the drug. All of these factors make immunotoxicity testing of BRMs a challenge to toxicologists working in this field.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
